[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100474589":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":11,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Shenzhen Geno-Immune Medical Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"4SCAR T Cell Therapy for autoimmune diseases","EXPERIMENTAL",null,[13],"Biological: 4SCAR T cells",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","4SCAR T cells","Infusion of 4SCAR T cells at 10\\^6 cells\u002Fkg body weight via IV",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Lung-Ji Chang, PhD","CONTACT","+86 0755-86573763","c@szgimi.org",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Shenzhen Geno-immune Medical Institute","RECRUITING","Shenzhen","Guangdong","518000","China","CN",{"type":36,"coordinates":37},"Point",[38,39],114.0683,22.54554,{"lat":39,"lon":38},[42],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},{"type":44,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100474589","phase-1-car-t-cells-targeting-autoimmune-diseases-100474589",false,"NCT05459870","CAR-T Cells Targeting Autoimmune Diseases","CAR-T Cells Targeting B Cell Related Autoimmune Diseases","Inclusion Criteria:\n\n1. age older than 18 years.\n2. expression of B cell surface molecules.\n3. the KPS score over 80 points, and survival time is more than 3 months.\n4. greater than Hgb 80 g\u002FL.\n5. no contraindications to blood cell collection.\n\nExclusion Criteria:\n\n1. accompanied with other active diseases and difficult to assess treatment response.\n2. bacterial, fungal, or viral infection, unable to control.\n3. living with HIV.\n4. active HBV or HCV infection.\n5. pregnant and nursing mothers.\n6. under systemic steroid treatment within a week of the treatment.\n7. prior failed CAR-T treatment.","ALL","18 Years","75 Years",{"count":56,"type":57},30,"ESTIMATED","INTERVENTIONAL",[60,61],"PHASE1","PHASE2","The purpose of this study is to assess the feasibility, safety and efficacy of CAR-T cell therapy in patients with autoimmune disease. Another goal of the study is to learn more about the safety and function of the CAR-T cells and their persistency in autoimmune disease patients.",[64],"Autoimmune Diseases",[66,67,68,69,70,71,72],"CAR-T","autoimmune disease","autoantibody","CD19","BCMA","CD138","BAFF-R","2026-06-18",{"date":75,"type":76},"2026-06-23","ACTUAL",{"date":78,"type":76},"2026-06-01",{"date":80,"type":57},"2030-12-31",{"name":5,"class":6},1]